Nipocalimab: A promising treatment for newborns and fetuses with early-onset severe hemolytic disease?

Published Date: 22 Oct 2023

Data from the phase 2 UNITY study presented at the 2023 American Academy of Pediatrics National Conference and Exhibition suggest that nipocalimab (Janssen) may be promising for the antenatal and postnatal management of fetal anemia in pregnancies with a high risk of EOS-HDFN.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot